AstraZeneca Pharma India Limited (AZPIL), a subsidiary of AstraZeneca Plc, the esteemed British-Swedish multinational pharmaceutical and biotechnology conglomerate, has been a pioneering force in India’s healthcare sector since its inception in 1979.
On March 6, 2025, AstraZeneca Pharma India Ltd announced that it has secured regulatory approval from India’s drug authority to import and market sodium zirconium cyclosilicate powder for oral suspension, an advanced treatment for hyperkalaemia—elevated potassium levels in the bloodstream—in adult patients.
The authorisation, granted by the Central Drugs Standard Control Organisation (CDSCO), Directorate General of Health Services, Government of India, permits the importation of sodium zirconium cyclosilicate powder for oral suspension in 5g and 10g formulations (Lokelma).
AstraZeneca Pharma India conveyed in a regulatory filing that this approval paves the way for the imminent launch of Lokelma in India, contingent upon the acquisition of requisite statutory clearances.
In a recent milestone, AstraZeneca, in February, secured CDSCO’s approval for the sale of its esteemed oncology medication, Durvalumab.
This regulatory nod encompasses the import, sale, and distribution of Durvalumab solution for infusion in 120mg/2.4ml and 500mg/10ml variants (Imfinzi) for an additional therapeutic indication, reinforcing the company’s commitment to expanding its oncological portfolio in India.
AstraZeneca Pharma India Ltd. exhibited an exceptional performance in Q3 FY25, reporting a remarkable 44% year-on-year surge in revenue from operations, reaching ₹440.29 crore, a substantial escalation from ₹305.79 crore in the corresponding period of the previous fiscal year.
The company’s net profit soared to ₹54.68 crore, a staggering increase from ₹15.80 crore in Q3 FY24, underscoring its robust growth trajectory and strategic excellence in the Indian pharmaceutical market.
At 10:45 AM on March 7, 2025, AstraZeneca Pharma India Ltd. shares traded 0.40% up at ₹7,496.60 per share on the NSE.
AstraZeneca Pharma India Ltd is set to expand treatment options for hyperkalaemia in adult patients, reinforcing its commitment to bringing innovative and effective therapies to the Indian healthcare market.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Mar 7, 2025, 2:53 PM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
